Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome

Marie, I.; Josse, S.; Decaux, Olivier; Dominique, S.; Diot, Élisabeth; Landron, C.; Roblot, P.; Jouneau, S.; Hatron, Pierre‐Yves; Tiev, Kiet; Vittecoq, Olivier; Noël, Danièle; Mouthon, Luc; Ménard, Jean-François; Jouen, F.

doi:10.1016/j.autrev.2012.01.006

Cited by 181 publications

(130 citation statements)

References 49 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Therefore, caution must be exerted when interpreting the imaging, and HRCT patterns cannot be directly transposed into histological considerations. HRCT findings do not differ significantly between the various presentations of polymyositis-or dermatomyositis-ILD [81]; however, acute and subacute onset of ILD seem to be associated with more frequent and more extensive consolidation, which is the hallmark of this ILD subtype. Other HRCT features include diffuse patchy ground-glass opacity, basal irregular lines and some reticulation [63].…”

Section: Pathogenesismentioning

confidence: 71%

“…The risk of acute evolution of ILD and mortality are generally not increased in patients with anti-ARS antibodies compared with the other autoantibodies [52,81,96,100]. Among patients with anti-ARS antibodies, the risk of pulmonary worsening and death seems to be similar in those with anti-Jo1 and non-Jo1 antibodies, but conclusions diverge according to the study [4,8,15,111].…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Idiopathic inflammatory myopathies and the lung

et al. 2015

View full text Add to dashboard Cite

Idiopathic inflammatory myositis (IIM) is a group of rare connective tissue diseases (CTDs) characterised by muscular and extramuscular signs, in which lung involvement is a challenging issue. Interstitial lung disease (ILD) is the hallmark of pulmonary involvement in IIM, and causes morbidity and mortality, resulting in an estimated excess mortality of 50% in some series. Except for inclusion body myositis, these extrapulmonary disorders are associated with the general and visceral involvement frequently found in other CTDs including fever, Raynaud's phenomenon, arthralgia, nonspecific cutaneous modifications and ILD, for which the prevalence is estimated to be up to 65%. Substantial heterogeneity exists within the spectrum of IIMs, and each condition is associated with various frequencies and subtypes of pulmonary involvement. This heterogeneity is partly related to the presence of various autoantibodies encompassing anti-synthetase, anti-MDA5 and anti-PM/Scl. ILD is present in all subsets of IIM including juvenile myositis, but is more frequent in dermatomyositis and overlap myositis. IIM can also be associated with other presentations of respiratory involvement, namely pulmonary arterial hypertension, pleural disease, infections, drug-induced toxicity, malignancy and respiratory muscle weakness. Here, we critically review the current knowledge about adult and juvenile myositis-associated lung disease with a detailed description of therapeutics for chronic and rapidly progressive ILD. @ERSpublications Interstitial lung disease is a leading cause of morbidity in dermatomyositis/polymyositis

show abstract

Section: Pathogenesismentioning

confidence: 71%

Section: Discussionmentioning

confidence: 90%

Idiopathic inflammatory myopathies and the lung

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Other case studies have suggested a possible link between antisynthetase antibodies and malignancy [53,54]. Interestingly, one study found that anti-Jo-1 is more commonly associated with malignancy [55] when compared to other antisynthetase antibodies such as anti-PL7 and -PL12. Although anti-Jo1 by itself has been found in some studies to be a protective factor [41,56] other reports suggest just the opposite [7,57,58].…”

Section: Factors Associated With the Absence Of Malignancymentioning

confidence: 99%

Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review

Tiniakou

Mammen

2015

Clinic Rev Allerg Immunol

114

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases (collectively known as myositis) affecting the skeletal muscles as well as other organ systems such as skin, lungs, and joints. The primary forms of myositis include polymyositis (PM), dermatomyositis (PM), and immune-mediated necrotizing myopathy (IMNM). Patients with these diseases experience progressive proximal muscle weakness, have characteristic muscle biopsy findings, and produce autoantibodies that are associated with unique clinical features. One distinguishing feature of these patients is that they are also known to have an increased risk of cancer. Since the first description of the association in 1916, it has been extensively reported in the medical literature. However, there have been significant variations between the different studies with regard to the degree of cancer risk in patients with IIM. These discrepancies can, in part, be attributed to differences in the definition of malignancy-associated myositis used in different studies. In recent years, significant advances have been made in defining specific features of IIM that are associated with the development of malignancy. One of these has been myositis-specific antibodies (MSAs), which are linked to distinct clinical phenotypes and categorize patients into groups with more homogeneous features. Indeed, patients with certain MSAs seem to be at particularly increased risk of malignancy. This review attempts a systematic evaluation of research regarding the association between malignancy and myositis.

show abstract

“…It is possible that the prevalence of the non-Jo1 ARS group is higher in different cohorts such as patients labelled as 'idiopathic' IP, particularly in those with UIP and AIP (DAD) subtypes [27]. Data from several studies suggest that UIP and AIP are commonly seen in non-Jo1 ASS, in particular anti-EJ, anti-PL7 and anti-PL12 patients, where lung disease presents early in disease course and is the predominant manifestation [22,[27][28][29][30][31][32]. In a large series of Japanese patients positive for anti-Jo-1, anti-EJ, anti-PL-7, anti-PL-12, anti-KS or anti-OJ highlighted the degree of heterogeneity within ASS in terms of distribution and onset of myositis, lung disease and skin lesions [33].…”

Section: Anti-synthetase Syndromementioning

confidence: 99%

The Clinical Features of Myositis-Associated Autoantibodies: a Review

Gunawardena

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases traditionally defined by clinical manifestations including skeletal muscle weakness, skin rashes, elevated skeletal muscle enzymes, and neurophysiological and/or histological evidence of muscle inflammation. Patients with myositis overlap can develop other features including parenchymal lung disease, inflammatory arthritis, gastrointestinal manifestations and marked constitutional symptoms. Although patients may be diagnosed as having polymyositis (PM) or dermatomyositis (DM) under the IIM spectrum, it is quite clear that disease course between subgroups of patients is different. For example, interstitial lung disease may predominate in some, whereas cutaneous complications, cancer risk, or severe refractory myopathy may be a significant feature in others. Therefore, tools that facilitate diagnosis and indicate which patients require more detailed investigation for disease complications are invaluable in clinical practice. The expanding field of autoantibodies (autoAbs) associated with connective tissue disease (CTD)-myositis overlap has generated considerable interest over the last few years. Using an immunological diagnostic approach, this group of heterogeneous conditions can be separated into a number of distinct clinical phenotypes. Rather than diagnose a patient as simply having PM, DM or overlap CTD, we can define syndromes to differentiate disease subsets that emphasise clinical outcomes and guide management. There are now over 15 CTD-myositis overlap autoAbs found in patients with a range of clinical manifestations including interstitial pneumonia, cutaneous disease, cancer-associated myositis and autoimmune-mediated necrotising myopathy. This review describes their diagnostic utility, potential role in disease monitoring and response to treatment. In the future, routine use of these autoAb will allow a stratified approach to managing this complex set of conditions.

show abstract

Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome

Cited by 181 publications

References 49 publications

Idiopathic inflammatory myopathies and the lung

Idiopathic inflammatory myopathies and the lung

Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review

The Clinical Features of Myositis-Associated Autoantibodies: a Review

Contact Info

Product

Resources

About